RT Venus Protocol (@VenusProtocol)Monthly users just doubled.More volume, same seamless experience.Venus is where DeFi moves.Source: @tokenterminal https://t.co/WpvZ7ejSYI ...

近日， 上海人工智能实验室青年研究员 谈攀 联 合 上海交通大学自然科学研究院/物理天文学院/张江高研院/药学院 洪亮 教授团队，在 Nature Communications 期刊发表了题为： Harnessing Protein Language Model for Structure-Based Discovery of Highly Efficient and Robust PET Hydrolases 的研究论文。 该研究发布了用于酶挖掘的蛋白质大模型—— VenusMine ，该 模型融合了蛋白质语言大模型与三维结构分析，通过蛋白质序列、结构和功能之间的隐含映射规则，能在海量的蛋白 数据库中高效挖掘同源性低但功能优异的酶分子。 应用该模型，研究团队成功发现了一系列 PET 水解酶，其中来自 Kibdelosporangium banguiense 的 KbPETase 表现出极高的催化效 率和热稳定性，其最适酶活是模板 IsPETase 的 97 倍。 编辑丨王多鱼 排版丨水成文 塑料废弃物，带来了重大环境挑战，尤其是 聚对苯二甲酸乙二醇酯 （PET） ，是当今使用量最大的饮料包装，用于 碳酸饮料 ...

Don’t Miss This Weekend’s Sky Show — Venus And A Stunning Star Cluster https://t.co/AhvHPSgyKG ...

Core Insights - Venus Concept Inc. has successfully exchanged $6.5 million of subordinated convertible notes for 325,651 shares of Series Y preferred stock, resulting in a 14% reduction in total debt obligations from $39.7 million to approximately $34.3 million [1][2] Group 1: Financial Position - The debt exchange improves the Company's balance sheet and provides financial flexibility for ongoing strategic initiatives, including the divestiture of the Venus Hair business [2] - The total debt reduction reflects the Company's commitment to optimizing its capital structure [2] Group 2: Management Commentary - The CEO of Venus Concept emphasized the importance of the partnership with Madryn Asset Management in achieving financial flexibility and supporting the Company's transformation plan [2] - Madryn Asset Management expressed support for the management team and the Company's efforts to return to growth [2] Group 3: Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products across over 60 countries [4] - The product portfolio includes various aesthetic device platforms and hair restoration systems, backed by prominent healthcare industry investors [4]

Daktronics (DAKT) Q4 2025 Earnings Call June 25, 2025 11:00 AM ET Company Participants Carla Gatzke - VP - Human Resources & Corporate SecretaryAndrew Siegel - ChairmanBrad Wiemann - EVP, Interim President & CEOHoward Atkins - Acting CFO, Treasurer & Chief Transformation Officer Conference Call Participants Aaron Spychalla - Senior Research AnalystAnja Soderstrom - Senior Equity Research AnalystMac Furst - Research Analyst Operator Good day, and thank you for standing by. Welcome to the Daktronics Fourth Qu ...

Financial Data and Key Metrics Changes - The company reported a strong finish to a transformational year, with a 29% increase in backlog from Q3 and a 17% year-over-year increase [15][39] - Adjusted operating income for 2025 was $50 million, down from a record $87 million in 2024, with an adjusted operating income margin of 6.6% compared to 10.6% in 2024 [36][39] - Operating cash flow more than doubled year-over-year, with a 54.5% growth for the year, totaling $97.7 million [32][41] Business Line Data and Key Metrics Changes - In the Live Events segment, orders decreased 12% year-over-year, but the company expects continued growth due to new projects and repeat customers [20][18] - The Commercial business saw a 31% increase in orders for the year and a 44% increase in Q4 compared to the previous year, driven by strong demand in out-of-home advertising [21][22] - Transportation orders decreased 10% year-over-year but increased 14% from Q4, supported by notable wins in intelligent transportation systems [23][24] Market Data and Key Metrics Changes - International orders grew 32% year-over-year and more than doubled from Q4 of the previous year, with significant contributions from advertising orders in various countries [25][26] - The High School Park and Recreation business experienced record orders, growing 19% for the year and 33% for Q4, driven by strong adoption of video solutions [27][28] Company Strategy and Development Direction - The company is focused on achieving higher operating margins of 10% to 12% and a return on invested capital (ROIC) target of 17% to 20% by fiscal year 2028 [47] - The transformation plan includes value-based pricing, revenue mix diversification, and new product introductions to drive growth [48] - The company is committed to maintaining a strong balance sheet and investing in high-growth, high-margin business products [41][42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about revenue growth in FY 2026, supported by a strong backlog and order flow [55][39] - The company is adapting to the tariff environment and remains flexible in its pricing and supply chain strategies [49][50] - Management emphasized the importance of executing the transformation plan and achieving long-term financial objectives [51][52] Other Important Information - The company incurred $16.5 million in non-recurring expenses related to transformation initiatives, with $7.5 million in Q4 [34][35] - A new $10 million share repurchase program was approved by the board, following a previous program [76] Q&A Session Summary Question: Revenue growth outlook for FY 2026 - Management indicated that all markets are expected to show growth, aligning with the 7% to 10% compound annual growth rate target through FY 2028 [55][56] Question: Margin outlook and tariff impacts - Management discussed implementing value-based pricing and driving operational efficiencies to improve margins, despite tariff uncertainties [57][58] Question: Update on commercial segment and AV network expansion - Management highlighted optimism in the commercial business, particularly in out-of-home advertising, and plans to aggressively grow the AV integrator space [60][61] Question: Working capital and capital allocation - Management stated that the primary use of capital will be for growth initiatives, product development, and digital transformation, with share repurchase also being considered [64][66] Question: Strength of international orders and future expectations - Management noted significant growth in international orders and a strong pipeline, which is expected to contribute to revenue growth in FY 2026 [72][73] Question: Future consulting fees related to transformation initiatives - Management confirmed that no additional consulting fees are expected for the completed transformation initiatives, but some new initiatives may arise [74][75]

Core Viewpoint - Venus Concept Inc. has successfully closed a registered direct offering, raising approximately $1.15 million, with potential additional proceeds of up to $2.3 million from unregistered short-term warrants [1][3]. Group 1: Offering Details - The company sold 434,720 shares of common stock at a price of $2.65 per share [1]. - Concurrently, unregistered short-term warrants were issued to purchase up to 869,440 shares at the same exercise price, which are immediately exercisable and will expire in eighteen months [1][3]. - The gross proceeds from the offering are approximately $1.15 million before fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes [3]. Group 3: Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products across over 60 countries [7]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare growth equity investors [7].

$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrantsTORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share in a registered direct offering ...

Core Viewpoint - Venus Concept Inc. has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd for $20 million in cash, which is expected to enhance the company's financial condition and support strategic growth initiatives [1][2][3] Group 1: Transaction Details - The transaction is valued at $20 million, subject to customary working capital adjustments [1] - The sale includes the portfolio of hair restoration and hair transplant technologies, related equipment, services, and intellectual property, specifically for ARTAS and NeoGraft [2][3] - The transaction is anticipated to close in the third quarter of 2025, pending certain closing conditions [3] Group 2: Financial Impact - The revenue from the sale of ARTAS and NeoGraft systems, procedure kits, and warranty revenue was approximately $12.5 million in fiscal year 2024 [3] - Cash used in operations related to the hair restoration and transplant businesses totaled approximately $6.7 million in fiscal year 2024 [3] Group 3: Strategic Rationale - The CEO of Venus Concept stated that the transaction allows the company to focus on its global medical aesthetics business, which is expected to improve revenue growth and lower operating expenses [2] - Meta Healthcare Group aims to leverage the acquired technologies to expand its hair loss-related business areas and enhance R&D and manufacturing capabilities [2][5]

Stoke Therapeutics (STOK) 2025 Conference June 04, 2025 01:25 PM ET Speaker0 Yeah. I mean, it truly does differentiate your medicine. Speaker1 Right. Are you ready? Yep. Okay. We're gonna get started with our next session. I'm Andrew Tsai, senior biotech analyst at Jefferies. Thanks for joining me today. It's my pleasure to have Stokes Interim CEO, Ian Smith, by my side today. Welcome, Ian. Speaker0 Thank you, Andrew. Speaker1 Thank you. Yep. And so maybe spend the next couple minutes discussing Stokes, wha ...